Flagg Flanagan, Chairman and CEO

Oct. 12 | 3:15pm | BlueRock Therapeutics Ballroom

Salt Lake City, UT

In-person Presentation

DiscGenics is a privately held, clinical-stage biopharmaceutical company developing regenerative cell-based therapies that alleviate pain and restore function in patients with degenerative diseases of the spine. DiscGenics’ first product candidate, IDCT, is a homologous, allogeneic, injectable cell therapy that utilizes biomedically engineered progenitor cells derived from intervertebral disc tissue, known as Discogenic Cells, to offer a non-surgical, potentially regenerative solution for the treatment of patients with mild to moderate degenerative disc disease. IDCT is being evaluated in two parallel regulatory-allowed, prospective, randomized, double-blinded, controlled, multicenter clinical trials in the U.S. and Japan.

By using this website you agree to accept our Privacy Policy and Terms & Conditions